Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$250.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Zealand Pharma A/S Comments on FY 2012 Financial Guidance


Tuesday, 13 Nov 2012 02:30am EST 

Zealand Pharma A/S announced that it retains its revenue guidance for the fiscal year 2012 of DKK 224 million (EUR 30 million) with related royalty expenses of DKK 16 million (EUR 2 million). Full fiscal year 2012 guidance on net operating expenses has been adjusted to a range of between DKK 167 million and DKK 177 million (between EUR 22 million and EUR 24 million) from the previous range of between DKK 150 million and DKK 170 million (between EUR 20 million and EUR 23 million) as a reflection of an increased activity level in the fourth quarter of the fiscal year 2012. As a result, the Company now expects a positive net result for the fiscal year 2012 at a range of between DKK 30 million and DKK 40 million (between EUR 4 million and EUR 5 million), compared with the previously expected range of between DKK 37 million and DKK 57 million (between EUR 5 million and EUR 8 million). According to I/B/E/S Estimates, analysts on average are expecting the Company to report fiscal year 2012 revenue of DKK 216.52 million. 

Company Quote

70.0
-1.0 -1.41%
10:59am EDT